Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Livzon Pharmaceutical Group ( (HK:1513) ) has shared an announcement.
Livzon Pharmaceutical Group Inc. has received approval from the National Medical Products Administration to conduct clinical trials for its new siRNA-based drug, YJH-012 injection, targeting gout. This development marks a significant step in the company’s efforts to innovate within the pharmaceutical industry, as there are currently no similar small RNA products on the domestic market, potentially positioning Livzon as a leader in this niche. However, the company acknowledges the inherent risks and uncertainties associated with drug development and market competition, advising investors to be cautious.
The most recent analyst rating on (HK:1513) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a company operating in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in innovative drug development, particularly in the field of siRNA technology, which aims to provide advanced treatment options for various medical conditions.
Average Trading Volume: 1,481,281
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$32.28B
Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.